Invention Grant
- Patent Title: Treatment of cancer cells overexpressing somatostatin receptors using ocreotide derivatives chelated to radioisotopes
-
Application No.: US16477623Application Date: 2018-01-12
-
Publication No.: US11541133B2Publication Date: 2023-01-03
- Inventor: Izabela Tworowska , Nilesh Wagh , Ebrahim S. Delpassand , Federico Rojas-Quijano , Paul Jurek , Garry E. Kiefer , Tania A. Stallons , Amal Saidi , Julien Torgue
- Applicant: RADIOMEDIX INC. , ORANO MED
- Applicant Address: US TX Houston; FR Courbevoie
- Assignee: RADIOMEDIX INC.,ORANO MED
- Current Assignee: RADIOMEDIX INC.,ORANO MED
- Current Assignee Address: US TX Houston; FR Courbevoie
- Agency: ArentFox Schiff LLP
- International Application: PCT/US2018/013640 WO 20180112
- International Announcement: WO2018/132751 WO 20180719
- Main IPC: A61K51/08
- IPC: A61K51/08 ; A61P35/00 ; A61K51/04 ; A61K47/10 ; A61K47/12 ; A61K47/18 ; A61K47/22 ; A61K45/06

Abstract:
A cancer targeting composition, kit, and method for treatment of cancer cells overexpressing somatostatin receptors is disclosed. The composition includes a radioisotope, a chelator, and a targeting moiety. The chelator includes a nitrogen ring structure including a tetraazacyclododecane, a triazacyclononane, and/or a tetraazabicyclo [6.6.2] hexadecane derivative. The targeting moiety includes a somatostatin receptor targeting peptide. The somatostatin receptor targeting peptide includes an octreotide derivative. The targeting moiety is chelated to the radioisotope by the chelator whereby the cancer cells are targeted for elimination.
Public/Granted literature
Information query